Trump Directs FDA to Expedite Psychedelic Drug Reviews, Commits $50M to Ibogaine Research

**TL;DR** President Trump has issued an executive order directing the Food and Drug Administration (FDA) to expedite the review process for psychedelic drugs like ibogaine. The United States will also allocate $50 million to federal research specifically for ibogaine.

**Context** Psychedelic drugs, compounds known to alter perception and mood, currently face significant regulatory hurdles. These substances, including ibogaine—derived from a central African shrub root—can induce hallucinations and remain largely illegal. Research continues to explore their potential therapeutic applications, particularly for conditions such as post-traumatic stress disorder (PTSD) and substance abuse.

**Key Facts** The executive order compels the FDA to accelerate its review of psychedelic drugs. This directive aims to streamline the path for compounds like ibogaine through the regulatory process. Separately, the United States has committed $50 million in federal funding for research into ibogaine. This allocation supports further scientific investigation into its efficacy and safety. President Trump stated that if these drugs "turn out to be as good as people are saying," they could have "a tremendous impact on this country and other countries, too." The drug has been explored for its potential in treating opioid addiction and PTSD, with veteran groups advocating for its study.

**What It Means** This move signals a federal push to explore the medical applications of psychedelics. Expedited FDA review could reduce the time required for drugs to move from clinical trials to market access, pending evidence of safety and efficacy. The $50 million research fund specifically targets ibogaine, expanding scientific understanding of its mechanisms and potential benefits. These actions could pave the way for reclassification of these drugs, provided successful clinical trials demonstrate their therapeutic value. Watch for the FDA's implementation of the executive order and the initial outcomes of federally funded ibogaine research as key indicators of future developments.